Endocrine disorders are important, potentially reversible causes of impotence. Impotence may be an early manifestation of hypopituitarism, nonfunctioning pituitary tumors, prolactin-secreting pituitary tumors, or hyperthyroidism. Treatment of these disorders, as well as many of the other endocrinopathies with which impotence may be associated, usually leads to restoration of libido and potency. When impotence is caused by the autonomic neuropathy of diabetes, however, treatment of the endocrinopathy rarely restores sexual function. Sex therapy or implantation of a penile prosthesis may be useful in selected patients with this cause of impotence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00325481.1983.11698466 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiosurgery versus radiation therapy for long term local control rate of craniopharyngioma: a meta-analysis.
Neurosurg Rev
January 2025
Department of Neurosurgery, Korea University Guro Hospital, Korea University Medical College, Seoul, Korea.
Introduction: Craniopharyngiomas are challenging benign tumors arising from Rathke's pouch remnants, often requiring multidisciplinary management due to their proximity to critical neurovascular structures. This meta-analysis systematically compares conventional radiation therapy (RT) and stereotactic radiosurgery (RS) in treating residual or recurrent craniopharyngiomas.
Method: A comprehensive literature search identified 44 studies, including 46 reports, meeting inclusion criteria such as progression-free survival (PFS) and post-radiotherapy complications.
Diagnostic value of 11C-Methionine PET-CT imaging in persistent or recurrent Cushing's disease after surgery.
J Clin Endocrinol Metab
January 2025
Department of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc UCL, Bruxelles, Belgium.
Introduction: Equivocal or negative pituitary magnetic resonance imaging (MRI) findings raise a significant challenge in the management of persistent or recurrent Cushing's disease (CD), compromising the chances of success of a further transsphenoidal surgery (TSS). The aim of our study was to determine the diagnostic utility of 11C-methionine (MET) positron emission tomography coupled with computerized tomography (PET/CT) in localizing the residual or relapsing corticotroph adenoma.
Methods: We retrospectively analyzed the results of 11C-MET PET/CT performed in two tertiary medical centers between May 2002 and November 2023 in 22 patients with a persisting or recurrent CD after initial TSS and equivocal or negative pituitary MRI findings.
Cell signaling communication within papillary craniopharyngioma revealed by an integrated analysis of single-cell RNA sequencing and bulk RNA sequencing.
J Transl Med
January 2025
Laboratory of Gene Engineering and Genomics, School of Basic Medical Sciences, Chengde Medical University, Chengde, 067000, China.
Objective: This study aims to elucidate the primary signaling communication among papillary craniopharyngioma (PCP) tumor cells.
Methods: Five samples of PCP were utilized for single-cell RNA sequencing. The most relevant ligand and receptor interactions among different cells were calculated using the CellChat package in R software.
The Economic Burden of Management of Pituitary Adenomas: A Propensity-Score-Matched Cost Analysis.
J Otolaryngol Head Neck Surg
January 2025
Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, Ottawa, ON, Canada.
Importance: Pituitary adenomas (PAs) present a notable economic burden on healthcare systems due to their management's reliance on multimodal, often costly interventions.
Objective: To determine total and relative healthcare costs for PAs at Ontario-based institutions.
Design: A retrospective, propensity-score-matched cohort analysis.
Tumor-Induced Osteomalacia Localized by Systemic Venous Sampling and Ga-DOTATOC Positron Emission Tomography.
JCEM Case Rep
February 2025
First Department of Internal Medicine, Wakayama Medical University, Wakayama City, Wakayama 641-8509, Japan.
Tumor-induced osteomalacia is characterized by hypophosphatemia and fragility fractures caused by fibroblast growth factor 23 (FGF23)-producing tumors. We report a case of tumor-induced osteomalacia in which the tumor location could be determined by gallium 68 (Ga)-DOTATOC positron emission tomography (PET)/computed tomography (CT). A 74-year-old woman had recurrent fractures and bone pain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!